Skip to main content
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. — Investor Relations & Filings

Ticker · BCAX ISIN · US0554771032 US Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country US United States of America
Listing US BCAX

About Bicara Therapeutics Inc.

https://www.bicara.com/

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class, dual-action biologics for cancer treatment. The company engineers bifunctional therapies that combine the precision of targeted treatments with the activation of a potent and durable anti-tumor immune response. This approach is designed to deliver therapeutic impact directly within the tumor microenvironment, with a primary focus on developing treatments for patients with solid tumors.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 92% confidence The document is a SEC Form 8-K “Current Report” announcing a press release and exhibits. It does not present full financial statements or AGM materials, nor is it a proxy, dividend notice, earnings release, M&A filing, etc. It is a general regulatory filing under the Exchange Act, so it falls under the Regulatory Filings (RNS) category.
2026-05-21 English
10-Q - Bicara Therapeutics Inc. (0002023658) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
Regulatory Filings
2026-05-11 English
ARS - Bicara Therapeutics Inc. (0002023658) (Filer)
Annual Report FY 2025
2026-04-27 English
DEF 14A - Bicara Therapeutics Inc. (0002023658) (Filer)
Proxy Solicitation & Information Statement
2026-04-27 English
8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
Annual Report Classification · 95% confidence The document is a detailed press release reporting the fourth quarter and full year 2025 financial results of Bicara Therapeutics. It includes comprehensive financial data such as operating expenses, net loss, cash position, and detailed business updates including clinical trial progress and corporate highlights. The presence of full financial statements and substantive financial analysis for a full fiscal year indicates this is a comprehensive annual financial report. The document also mentions the fiscal year ended December 31, 2025, which aligns with an annual reporting period. Although it is presented as a press release, the depth and breadth of financial data and business updates are consistent with an Annual Report or Earnings Release. However, since it covers the full year and includes detailed financial results, it is best classified as an Annual Report (10-K) type document rather than a brief Earnings Release (ER).
2026-03-30 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.